The Association between Glutathione S-Transferase M1 Genotype and Polycyclic Aromatic Hydrocarbon-DNA Adducts in Breast Tissue

  1. Andrew Rundle1,
  2. Deliang Tang,
  3. Jingzi Zhou,
  4. Stan Cho and
  5. Frederica Perera
  1. Division of Environmental Health Sciences, Joseph L. Mailman School of Public Health, Columbia University, New York, New York 10032

    Abstract

    A major goal in molecular epidemiology is to identify preventable environmental risk factors and susceptible subpopulations. In a hospital-based molecular epidemiological case-control study of breast cancer, we investigated the relationship between DNA damage from exposure to polycyclic aromatic hydrocarbons (PAHs) and susceptibility attributable to inherited deletion of the xenobiotic detoxifying gene, glutathione S-transferase M1 (GSTM1). Prior to breast surgery, women (n = 227) were enrolled and interviewed and donated a blood sample. PAH-DNA adduct levels were measured by immunohistochemistry in breast tissue samples retrieved from pathology blocks, and GSTM1 genotype was determined by PCR using WBC DNA. The GSTM1 analysis included 95 cases and 87 benign breast disease controls. GSTM1 genotype was not associated with breast cancer case-control status (odds ratio = 0.73; 95% confidence interval, 0.37–1.44). However, the GSTM1 null genotype predicted PAH-DNA adduct levels in malignant (β = 0.407; P = 0.003) and nonmalignant (β = 0.243; P = 0.05) breast tissue from cases. This relationship was not seen in tissue from controls (β = 0.095; P = 0.341). When tissue from controls was compared with tumor tissue from cases, there was a significant case-control difference in PAH-DNA adduct levels among women who were GSTM1 null. There was no such case-control difference among women who were homozygous or heterozygous for GSTM1. There was an interaction between GSTM1 and case-control status on adduct levels in breast tissue (P = 0.002). The results suggest that genetic susceptibility to the formation of PAH-DNA adducts in breast tissue may play a role in breast cancer development.

    Footnotes

    • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • 1 To whom requests for reprints should be addressed, at Molecular Epidemiology Program, Columbia School of Public Health, 60 Haven Avenue, Room B-109, New York, New York 10032.

    • 2 The abbreviations used are: BBD, benign breast disease; PAH, polycyclic aromatic hydrocarbon; ER, estrogen receptor; GSTM1, glutathione S-transferase M1; CPMC, Columbia-Presbyterian Medical Center; DCIS, ductal carcinoma in situ; OR, odds ratio; CI, confidence interval; ETS, environmental tobacco smoke.

      • Accepted July 13, 1900.
      • Received October 28, 1999.
      • Revision received June 6, 1900.
    « Previous | Next Article »Table of Contents